No Data
Fujian Cosunter Pharmaceutical (300436.SZ): The Innovative Drug Tai Zhong Ding for COVID-19 has been approved for market launch in Macau.
On January 8, Gelonghui reported that Fujian Cosunter Pharmaceutical (300436.SZ) announced that recently, its holding subsidiary, Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., received new drug market approval from the Macao Special Administrative Region's Drug Supervision Administration for the innovative drug Aitexan Tablets (Project code: GST-HG171) / Ritonavir Tablets combination packaging (Commodity name: Taizhongding), and obtained the drug registration certificate. Taizhongding showed superior results in preclinical and early clinical research initiated by researchers (IIT) compared to other COVID-19 treatments targeting the same pathway.
Fujian Cosunter Pharmaceutical (300436.SZ): The company has been re-certified as a national high-tech enterprise.
Gelonghui, December 30丨Fujian Cosunter Pharmaceutical (300436.SZ) announced that, according to the announcement released on December 30, 2024, by the Office of the Leading Group for the Management of National High-tech Enterprise Recognition, regarding the second batch of high-tech enterprises recognized in 2024 in Fujian Province, the company has been included in the "List of High-tech Enterprises for the Second Batch of Recognition in Fujian Province in 2024," with high-tech enterprise certificate number: GR202435002012, issued on December 4, 2024.
China Grants Fujian Cosunter Pharma Breakthrough Designation for Hepatitis B Drug; Shares Slide 5%
Fujian Cosunter Pharmaceutical (300436.SZ): The innovative drug for hepatitis B treatment, Nairikuwai GST-HG141, has been included in the list of breakthrough therapy products.
On December 15, Gelonghui reported that Fujian Cosunter Pharmaceutical (300436.SZ) announced that its Innovative Drugs holding subsidiary Fujian Guangsheng Zhonglin Biotechnology Co., Ltd. has had its hepatitis B treatment Innovative Drug GST-HG141 (English generic name "Neracorvir", Chinese generic name "奈瑞可韦") included in the list of breakthrough therapies by the National Medical Products Administration Drug Review Center (hereinafter referred to as the "Drug Review Center"), which is an acknowledgment of its significant clinical advantage data and is expected to accelerate the drug development process.
Fujian Cosunter Pharmaceutical (300436.SZ): received a total of 50.3444 million yuan in government subsidies and rewards.
On December 10, Gulonhui reported that Fujian Cosunter Pharmaceutical Co., Ltd. (300436.SZ) announced that on December 10, 2024, it and its Innovative Drugs holding subsidiary, Fujian Guangsheng Zhonglin Biotechnology Co., Ltd. (referred to as "Guangsheng Zhonglin"), collectively received 50.3444 million yuan in government subsidies and rewards, all of which have been received. The aforementioned government subsidy is a special reward fund to accelerate the high-quality development of the Biomedical industry in Fujian Province and support the research and development of Innovative Drugs, as well as recognition of the company's achievements in Innovative Drugs R&D.
Sinolink Securities: The favorable wind of medical policies arrives first, followed by innovation going abroad and performance reversal.
In 2025, Sinolink believes that the core investment opportunities in the pharmaceutical Sector will revolve around three main logics: 1) innovation going abroad; 2) demand recovery; 3) reversal of policy expectations.
Fujian Cosunter Pharmaceutical Co., Ltd.'s (SZSE:300436) Popularity With Investors Under Threat As Stock Sinks 25%